Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 11/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | LOX | P28300 | 1/20 | 0.49 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989460 | 0.83 | GRM5 (0.52) | GRM5MAOBAPPNR4A2 | |
| SCHEMBL3370181 | 0.83 | GRM5 (0.52) | GRM5MAOBAPPRECQLLOX | |
| SCHEMBL23931716 | 0.83 | MAOB (0.53) | GRM5MAOBRECQLLOXLOXL3 | |
| SCHEMBL25909143 | 0.80 | GRM5 (0.45) | GRM5MAOBAPPRECQLLOX | |
| SCHEMBL863713 | 0.80 | GRM5 (0.54) | GRM5MAOBAPPRECQLLOX | |
| SCHEMBL23931747 | 0.77 | GRM5 (0.51) | GRM5MAOBRECQLLOXLOXL3 | |
| SCHEMBL10157517 | 0.76 | LOXL2 (0.61) | GRM5RECQLLOXLOXL3LOXL2 | |
| SCHEMBL2896032 | 0.75 | MEN1 (0.51) | MAOBAPPRECQLNR4A2 | |
| SCHEMBL13722916 | 0.74 | RECQL (0.42) | GRM5MAOBRECQLLOXLOXL3 | |
| SCHEMBL1415532 | 0.74 | S1PR2 (0.46) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732456-B2 | Pyridone derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-08 | — | — | US | disclosed |
| WO-2009120655-A1 | INDOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 2009-10-01 | — | — | WO | disclosed |
| US-20070208046-A1 | Pyridone derivative | MSD K.K. (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1741703-A1 | PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208046-A1 | Pyridone derivative | CHRM1, XDH, MTR | GRM5 431/4885MAOB 203/4885APP 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.